[Vitamin K antagonist, direct oral anticoagulants: Where is the truth?]
Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are now in competition. The companies are trying to replace VKA by DOACs, totally or at least greatly VKA should VKA disappear in favor of DOACs? There are still many questions about DOACs. The purpose of this article is to make a well-considered decision in this area. The aim is not to denigrate one or the other but to share things between these two families of anticoagulants. Physicians using these drugs must have a full knowledge about compared efficacy and safety. We feel necessary to increase distance between effective results of the clinical trials and industrial communication around DOACs.
Service de médecine vasculaire, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address: jp-laroche@chu-montpellier.fr.
J-P
JP
Laroche
Département d'hématologie biologique, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address: jf-schved@chu-montpellier.fr.
J-F
JF
Schved
D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D032921:Consensus; D005602:France; D006801:Humans; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D014812:Vitamin K
Anticoagulant oral direct; Anticoagulation; Antivitamine K; Direct oral anticoagulants; Oral anticoagulant treatment; Vitamin K Antagonist